Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study-Reference-Cited by-同舟云学术

Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study

Published:2018-12 Issue:12 Volume:40 Page:2077-2087
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Kresa-Reahl Kiren,Repovic Pavle,Robertson Derrick,Okwuokenye Macaulay,Meltzer Leslie,Mendoza Jason P.

Funder

Biogen

Genzyme

Mallinckrodt

Novartis

Genentech,

GlaxoSmithKline

MedImmune

Roche

Sanofi-Genzyme

Sun Pharma

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference21 articles.

1. Update on disease-modifying therapies for multiple sclerosis;Vargas;J Investig Med,2017

2. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis;Gold;N Engl J Med,2012

3. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis;Fox;N Engl J Med,2012

4. Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study;Kappos;Mult Scler,2014

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic literature review of the measurement of patient-reported fatigue in studies of disease modifying therapies for multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-11

2. Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study;Neurology and Therapy;2024-06-27

3. De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate;Advances in Therapy;2024-06-11

4. Impact of Disease Modifying Therapy on MS-Related Fatigue: A Narrative Review;Brain Sciences;2023-12-20

5. Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study;Multiple Sclerosis Journal;2023-10-31